Oscar Health Expands Footprint, But Risk-Adjustment Overhang Persists

What happened

Oscar Health announced entry into South Carolina and expansion to 713 counties across 21 states for 2027, a 24% county increase. This growth move comes as the company navigates a sharp rise in risk-adjustment payables and post-subsidy membership attrition following enhanced APTC expiration. The expansion aligns with management's scale ambitions, but the master report indicates deteriorating balance-sheet swing factors, with net risk-adjustment payable reaching $3.974B in Q1'26. Liquidity remains ample, yet profitability is volatile, with Q1'26 benefitting from favorable reserve development and a temporary low MLR. While the expansion may support long-term operating leverage, near-term valuation hinges on risk-adjustment normalization and medical cost control.

Implication

Longer-term, expansion into new markets could enhance scale and diversify risk, but it also adds underwriting risk in unfamiliar populations. The master report suggests that until risk-adjustment accrual trends toward ~20% of direct premiums and net payable stabilizes, the stock may de-rate. Investors should monitor Q2'26 results for evidence of normalization and any change in membership guidance. The expansion is positive for long-term optionality, but does not change the near-term thesis that Q1 profitability is not repeatable. A cautious stance with reassessment in 3-6 months remains appropriate.

Thesis delta

The expansion plan is consistent with management's growth strategy, but it does not address the core concerns of risk-adjustment payables building and potential membership attrition after enhanced subsidies expired. The thesis remains POTENTIAL SELL; expansion adds execution risk and capital deployment scrutiny, but does not shift the valuation drivers. Until evidence shows sustainable underwriting profitability, the bear case remains intact.